Tag Archives: DES

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?

Revascularization Using DES in Infrapopliteal Disease: Meta-Analysis and Change of Paradigm?

Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise.

IVUS vs OCT para guiar la angioplastia ¿Cuál elegir?

IVUS-Guided Coronary Angioplasty: Promising Results at 3-Year Follow-Up

Intravascular ultrasound (IVUS) to guide drug-eluting stent (DES) implantation has been evaluated in several studies. Two randomized studies, IVUS-XPL (Impact of Intravascular Ultrasound Guidance on the Outcomes of Xience Prime Stents in Long Lesions) and ULTIMATE (Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-Comers Coronary Lesions), have shown fewer repeat revascularizations compared with angiography-guided

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

Should We Start Stenting with DES in Femoropopliteal Territory?

Percutaneous intervention of femoropopliteal lesions have been the standard strategy these past two decades. The development of drug eluting stents (DES) or drug eluting balloons (DEB) has improved patency rate compared against conventional balloon angioplasty. The ILLUMINA -a multicenter study- looked into the polymer free self-expanding stent NiTiDES, which showed at 1 year an 87%

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Drug Eluting Stents: Does Strut Size Matter?

The benefit of first-generation Drug-Eluting Stents (DES) over Bare Metal Stents (BMS) is largely known. Moreover, technological developments have led to reduced strut size, biodegradable polymers, and new scaffolds, which in turn have led to improved outcomes. These are known as ultrathin stents, and its struts measure between 70 and 100 microns, which contributes to

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

The Long Marathon of Ultrathin vs. 2nd Generation Thin-Strut DES

After 2.5 years of non-stop racing, ultrathin-strut drug-eluting stents (DES) reached the finish line before 2nd generation thin-strut DES. The advantage was in terms of clinically justified lesion revascularization, while rates of infarction, stent thrombosis, cardiac death, and all-cause death were similar. After failure at trying to create new generations of DES based on drugs

Más stents suman evidencia al esquema corto y nos acercamos al “efecto de clase”

Novel DES Technology Promises to Become the Next DES Generation

The novel technology of drug-eluting stent Supreme was designed to synchronize antiproliferative drug release and leave a base behind to promote healing. Accelerated endothelial healing after antiproliferative drug release may limit the long-term inflammatory response. This multicenter, single-blind study included 1600 patients who were randomized 2:1 to receive drug-eluting stent Supreme vs. a classic permanent-polymer everolimus-eluting

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny

EuroPCR 2021 | Ultrathin Struts Consolidate as Next DES Development

According to this recent meta-analysis of randomized studies, ultrathin strut devices are associated with lower rates of target vessel failure vs. 2nd generation drug eluting stents (DES). This advantage was driven by fewer clinically justified reinterventions.  This study was published in the European Heart Journal and simultaneously presented at EuroPCR 2021 Scientific Sessions. Ultrathin struts

Esquema corto y monoterapia, una práctica llena de evidencia

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme. The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons